PCRX · Pacira BioSciences, Inc.

The thesis

Pacira BioSciences is a takeover with a fixed price. Viatris has agreed to pay $36.50 per share in cash, and the shares closed at $36.39 on 30 October 2026. That leaves almost no room to outperform the S&P 500 over the next three months. The case is settled by the tender offer expiring at 11:59 p.m. Eastern on 16 November 2026 and by the Hart-Scott-Rodino (HSR) antitrust waiting period running out.

Viatris announced the deal on 8 October 2026, valuing Pacira's equity at $1.65 billion. It started the tender offer on 30 October 2026, according to Viatris's press release and its 8-K. Viatris expects to close by the end of 2026. The shares now move with the probability that the deal closes, not with Pacira's results or the healthcare sector. The narrative is saturated: the takeover has been public since 8 October 2026, every covering analyst cited here has moved to a neutral rating with a target at or near the offer price, and the shares have held within cents of $36.50 since then.

Bullish and bearish views on Pacira BioSciences, Inc.

The bull case on Pacira BioSciences, Inc. (PCRX), in brief: The deal has no financing condition. The bear case: The upside is capped at the offer.

Bull case

• The deal has no financing condition. Viatris will pay mainly from excess cash, with the rest from short-term borrowings. Its 8 October 2026 release says the impact on gross leverage will be minimal.
• Pacira's board backs the offer. The board approved the deal unanimously and recommends that stockholders tender, according to the Schedule 14D-9 described in coverage of the 30 October 2026 launch.
• No shareholder vote is needed for the second step. The merger follows the tender under Delaware Section 251(h). Holders who do not tender receive the same $36.50 in cash, per Investing.com's 30 October 2026 report on the offer terms.
• The products fit Viatris's pain business. Viatris said on 8 October 2026 that EXPAREL (acute pain after surgery) and ZILRETTA (osteoarthritis knee pain) complement its fast-acting meloxicam program. Viatris also expects the deal to add to its financial guidance metrics right away.

Bear case

• The upside is capped at the offer. The $36.39 close on 30 October 2026 sits just below the $36.50 cash price. The 52-week high of $36.42 is at the same level.
• A failed deal would remove the takeover premium. On 8 October 2026 the shares jumped 44.0% to $36.3 in one session on the news, Benzinga reported. If the deal breaks, that gain is what the shares would lose.
• Analysts have stopped recommending the shares. Needham and Jefferies cut their ratings to Hold on 8 October 2026, and Jefferies set a $36 target. On 9 October 2026 Truist cut to Hold and HC Wainwright cut to Neutral, both with $36.5 targets. RBC kept Sector Perform and raised its target to $36.5.
• The deal still needs two approvals. Closing requires more than 50% of outstanding shares to be tendered and the HSR waiting period to expire. No public source checked for this note confirms that HSR clearance has been granted.

Price setup

The shares closed at $36.39 on 30 October 2026, close to their 52-week high of $36.42, based on adjusted daily closes. They were up 31.8% over three months, and nearly all of that gain came from the 8 October 2026 jump. The 14-day relative strength index (RSI), a momentum gauge, was 54.3 on 30 October 2026. Benzinga flagged it above 83 on 16 October 2026.

Most of the buying since the announcement is likely from merger-arbitrage funds, which buy takeover targets to collect the small gap to the deal price. The sign of that is that the shares have held within cents of $36.50. There has been no share issuance, and SEC filings show no insider sales into the move. A sharp drop below the post-announcement range would be the first sign that the market doubts the deal will close.

Catalysts, next 30 days

• 16 November 2026, 11:59 p.m. Eastern: the tender offer expires unless it is extended or terminated. If it closes on time, Pacira holders receive $36.50 in cash. If Viatris extends it, that usually means a condition, most likely antitrust clearance, has not yet been met.
• HSR waiting period (date not disclosed): expiry or early termination of the antitrust waiting period is a condition of the offer. A second request from regulators would push the timeline past year-end.
• 29 December 2026: shares tendered but not yet accepted for payment can be withdrawn after this date. This matters only if the offer is still open then.
• ~31 December 2026, est.: Viatris's target to close the deal. A delay beyond this date would extend the deal risk into 2027.

What would change the view

The case breaks if the deal is in doubt. That would show up as Viatris ending the merger agreement, regulators issuing an HSR second request, or too few shares being tendered. In price terms, a daily close below $35.00 would show the market pricing real risk that the deal fails. The deal has held that range since 8 October 2026.

The case would also change if a competing bidder offered more than $36.50, which would reopen upside. No public report through 1 November 2026 points to another bidder. Until one of these happens, the shares can neither materially lead nor lag the S&P 500 except through a move in the index itself.

What it trades with

Until the deal closes, the shares are tied to the $36.50 offer. They have little sensitivity to the S&P 500, to biotech indices, or to Pacira's own quarterly sales. That makes outperformance over three months depend mainly on the index falling. Their main link to other stocks is through deal risk.

The M&A & special situations group, which includes SGRY, SKYA and ADT, has been heating up through late October 2026. That points to steady takeover activity, but each pending deal settles on its own conditions. A break in another healthcare deal on antitrust grounds would be the clearest sign of pressure on this spread. Viatris (VTRS) shares are exposed to the same deal from the buyer's side.